In June 2006, a quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil; Merck) was approved by the US FDA for the prevention of several diseases, including cervical cancer, that are caused by these types of human papillomavirus.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev. Cancer 2, 342–350 (2002).
Lowy, D. R. & Schiller, J. T. Prophylactic human papillo-mavirus vaccines. J. Clin. Invest. 116, 1167–1173 (2006).
Kirnbauer, R. et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA 89, 12180–12184 (1992).
Koutsky, L. A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645–1651 (2002).
Villa, L. L. et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre Phase II efficacy trial. Lancet Oncol. 6, 271–278 (2005).
Villa, L. L. et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24, 5571–5583 (2006).
FDA labelling information [online] (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Crum, C., Jones, C. & Kirkpatrick, P. Quadrivalent human papillo-mavirus recombinant vaccine. Nat Rev Drug Discov 5, 629–630 (2006). https://doi.org/10.1038/nrd2117
Issue Date:
DOI: https://doi.org/10.1038/nrd2117
This article is cited by
-
Biopharmaceutical benchmarks 2010
Nature Biotechnology (2010)
-
Interleukin 21: combination strategies for cancer therapy
Nature Reviews Drug Discovery (2008)
-
Biotrin assay to monitor cervical cancer exposure rates
Nature Biotechnology (2007)